Pediatric malignancies: Synopsis of current imaging techniques

Cancer Treatment and Research

Volumn 143, Issue , 2008, Pages 469-491

  Servaes, Sabah ^a   Epelman, Monica ^a   Pollock, Avrum ^a   Shekdar, Karuna ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IONIZING RADIATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; METASTASIS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PEDIATRICS; POSITRON EMISSION TOMOGRAPHY; REVIEW;

CHILD; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PEDIATRICS; POSITRON-EMISSION TOMOGRAPHY; RADIATION, IONIZING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48249140228     PISSN: 09273042     EISSN: 25098497     Source Type: Book Series    
DOI: 10.1007/978-0-387-75587-8_18     Document Type: Article

References (79)

1. Berry JD, Cook GJ. Positron emission tomography in oncology. Br Med Bull 2006.
2. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496-507.
3. Dizendorf EV, Treyer V, Von Schulthess GK, Hany TF. Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol 2002;179:477-81.
4. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: Prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006;47:1643-8.
5. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin's Lymphoma and Hodgkin's disease: Co-registered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004;232:823-9.
6. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004;45 Suppl 1:56S-65S.
7. Antoch G, Freudenberg LS, Stattaus J, et al. Whole-body positron emission tomography-CT: Optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002;179: 1555-60.
8. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: Introduction and evaluation. Radiology 2004;230:879-85.
9. Nanni C, Rubello D, Castellucci P, et al. 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. Biomed Pharmacother 2006;60:593-606.
10. Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006;36:524-31.
11. Miller E, Metser U, Avrahami G, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006;30:689-94.
12. Furth C, Denecke T, Steffen I, et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J Pediatr Hematol Oncol 2006;28: 501-12.
13. Arush MW, Israel O, Postovsky S, et al. Positron emission tomography/computed tomography with (18)fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007;.
14. Ben Arush MW, Bar Shalom R, Postovsky S, et al. Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol 2006;28:440-5.
15. Kavanagh PV, Stevenson AW, Chen MY, Clark PB. Nonneoplastic diseases in the chest showing increased activity on FDG PET. AJR Am J Roentgenol 2004;183:1133-41.
16. Blodgett TM, Casagranda B, Townsend DW, Meltzer CC. Issues, controversies, and clinical utility of combined PET/CT imaging: What is the interpreting physician facing? AJR Am J Roentgenol 2005;184:S138-45.
17. Schoder H, Gonen M. Screening for Cancer with PET and PET/CT: Potential and Limitations. J Nucl Med 2007;48 Suppl 1:4S-18S.
18. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: Comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-36.
19. Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: Comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36:1019-31.
20. Hoffer FA. Magnetic resonance imaging of abdominal masses in the pediatric patient. Semin Ultrasound CT MR 2005;26:212-23.
21. Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 2004;14:1829-41.
22. Kellenberger CJ, Epelman M, Miller SF, Babyn PS. Fast STIR whole-body MR imaging in children. Radiographics 2004;24:1317-30.
23. Laffan EE, O'Connor R, Ryan SP, V D. Whole-body magnetic resonance imaging: A useful additional sequence in paediatric imaging. Pediatr Radiol 2004;34:472-80.
24. Mazumdar A, Siegel MJ, V N, Luchtman-Jones L. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: A pilot study. AJR Am J Roentgenol 2002;179:1261-6.
25. Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: Techniques, clinical indications, and future applications. Semin Musculoskelet Radiol 2001;5:5-20.
26. Eustace SJ, Walker R, Blake M, Yucel EK. Whole-body MR imaging. Practical issues, clinical applications, and future directions. Magn Reson Imaging Clin N Am 1999;7:209-36.
27. Siegel MJ, Luker GG. Bone marrow imaging in children. Magn Reson Imaging Clin N Am 1996;4:771-96.
28. Mentzel HJ, Kentouche K, Sauner D, et al. Comparison of whole-body STIR-MRI and 99 mTc-methylene-diphosphonate scintigraphy in children with suspected multifocal bone lesions. Eur Radiol 2004;14:2297-302.
29. Levine DS, Navarro OM, Chaudry G, Doyle JJ, Blaser SI. Imaging the complications of bone marrow transplantation in children. Radiographics 2007;27:307-24.
30. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001;176:289-96.
31. Lowe LH, Isuani BH, Heller RM, et al. Pediatric renal masses: Wilms' tumor and beyond. Radiographics 2000;20:1585-603.
32. Panicek DM, Go SD, Healey JH, Leung DH, Brennan MF, Lewis JJ. Soft tissue sarcoma involving bone or neurovascular structures: MR imaging prognostic factors. Radiology 1997;205:871-5.
33. Riccabona M. (Paediatric) magnetic resonance urography: Just fancy images or a new important diagnostic tool? Curr Opin Urol 2007;17:48-55.
34. Nolte-Ernsting CC, Staatz G, Tacke J, Gunther RW. MR urography today. Abdom Imaging 2003;28:191-209.
35. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604-12.
36. Hunter JV, Wang ZJ. MR spectroscopy in pediatric neuroradiology. Magn Reson Imaging Clin N Am 2001;9:165,89, ix.
37. Lazareff JA, Gupta RK, Alger J. Variation of post-treatment H-MRSI choline intensity in pediatric gliomas. J Neurooncol 1999;41:291-8.
38. Tzika AA, Zurakowski D, Poussaint TY, et al. Proton magnetic spectroscopic imaging of the child's brain: The response of tumors to treatment. Neuroradiology 2001;43:169-77.
39. Cha S, Lu S, Johnson G, Knopp EA. Dynamic susceptibility contrast MR imaging: Correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 2000;11:114-9.
40. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891-9.
41. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: Dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11-29.
42. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881-90.
43. Siegal T, Rubinstein R, Tzuk-Shina T, Gomori JM. Utility of relative cerebral blood volume mapping derived from perfusion magnetic resonance imaging in the routine follow up of brain tumors. J Neurosurg 1997;86:22-7.
44. Olsen OE, Sebire NJ. Apparent diffusion coefficient maps of pediatric mass lesions with free-breathing diffusion-weighted magnetic resonance: feasibility study. Acta Radiol 2006;47:198-204.
45. Humphries PD, Wynne CS, Sebire NJ, Olsen OE. Atypical abdominal paediatric lymphangi-omatosis: Diagnosis aided by diffusion-weighted MRI. Pediatr Radiol 2006;36:857-9.
46. Murtz P, Flacke S, Traber F, van den Brink JS, Gieseke J, Schild HH. Abdomen: Diffusion-weighted MR imaging with pulse-triggered single-shot sequences. Radiology 2002;224:258-64.
47. Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Risk of chronic myeloid and acute leukemia mortality after exposure to ionizing radiation among workers at four U.S. nuclear weapons facilities and a nuclear naval shipyard. Radiat Res 2007;167:222-32.
48. Shuryak I, Sachs RK, Hlatky L, Little MP, Hahnfeldt P, Brenner DJ. Radiation-induced leukemia at doses relevant to radiation therapy: Modeling mechanisms and estimating risks. J Natl Cancer Inst 2006;98:1794-806.
49. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer 2005;103:1457-67.
50. Amthauer H, Furth C, Denecke T, et al. FDG-PET in 10 children with Non-Hodgkin's Lymphoma: Initial experience in staging and follow-up. Klin Padiatr 2005;217:327-33.
51. Collins CD. PET in lymphoma. Cancer Imaging 2006;6:S63-70.
52. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
53. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 2004;45:85-92.
54. Guermazi A, Juweid ME. Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma. Br J Radiol 2006;79:365-7.
55. Hermann S, Wormanns D, Pixberg M, et al. Staging in childhood lymphoma: Differences between FDG-PET and CT. Nuklearmedizin 2005;44:1-7.
56. Montravers F, McNamara D, Landman-Parker J, et al. (18) FDG in childhood lymphoma: Clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155-65.
57. Rini JN, Nunez R, Nichols K, et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 2005;35:169-78.
58. Willkomm P, Palmedo H, Grunwald F, Ruhlmann J, Biersack HJ. Functional imaging of Hodgkin's disease with FDG-PET and gallium-67. Nuklearmedizin 1998;37:251-3.
59. Juweid ME. Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin's Lymphoma. Hematology Am Soc Hematol Educ Program 2006;:259-65.
60. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-34.
61. Kellenberger CJ, Epelman M, Miller SF, Babyn PS. Fast STIR whole-body MR imaging in children. Radiographics 2004;24:1317-30.
62. Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: What pediatric health care providers should know. Pediatrics 2003;112:951-7.
63. Hsu SC, Metzger ML, Hudson MM, et al. Comparison of treatment outcomes of childhood Hodgkin's lymphoma in two US centers and a center in Recife, Brazil. Pediatr Blood Cancer 2006.
64. 2005-2006 Statistical Report: Primary Brain Tumors in the United States Statistical Report, 1998-2002 (Years Data Collected). Illinois, 2005 (http://www.cbtrus.Org/reports//2005-2006/ 2006report.pdf.).
65. Wang Z, Zimmerman RA, Sauter R. Proton MR spectroscopy of the brain: Clinically useful information obtained in assessing CNS diseases in children. AJR Am J Roentgenol 1996;167:191-9.
66. Papaioannou G, McHugh K. Neuroblastoma in childhood: Review and radiological findings. Cancer Imaging 2005;5:116-27.
67. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Radiologic-pathologic correlation. Radiographics 2002;22:911-34.
68. Andrich MP, Shalaby-Rana E, Movassaghi N, Majd M. The role of 131 iodine-metaiodoben-zylguanidine scanning in the correlative imaging of patients with neuroblastoma. Pediatrics 1996;97:246-50.
69. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129-34.
70. Ritchey ML, Kelalis PP, Haase GM, Shochat SJ, Green DM, D'Angio G. Preoperative therapy for intracaval and atrial extension of Wilms tumor. Cancer 1993;71:4104-10.
71. Ritchey ML, Shamberger RC, Haase G, Horwitz J, Bergemann T, Breslow NE. Surgical complications after primary nephrectomy for Wilms' tumor: Report from the National Wilms' Tumor Study Group. J Am Coll Surg 2001;192:63,8; quiz 146.
72. Grundy P, Perlman E, Rosen NS, et al. Current issues in Wilms tumor management. Curr Probl Cancer 2005;29:221-60.
73. Wilimas JA, Kaste SC, Kauffman WM, et al. Use of chest computed tomography in the staging of pediatric Wilms' tumor: Interobserver variability and prognostic significance. J Clin Oncol 1997;15:2631-5.
74. Owens CM, Veys PA, Pritchard J, Levitt G, Imeson J, Dicks-Mireaux C. Role of chest computed tomography at diagnosis in the management of Wilms' tumor: A study by the United Kingdom Children's Cancer Study Group. J Clin Oncol 2002;20:2768-73.
75. Rohrschneider WK, Werrich A, Rieden K, Darge K, Troger J, Graf N. US, CT and MR imaging characteristics of nephroblastomatosis. Pediatr Radiol 1998;28:435-43.
76. Gylys-Morin V, Hoffer FA, Kozakewich H, Shamberger RC. Wilms tumor and nephroblasto-matosis: Imaging characteristics at gadolinium-enhanced MR imaging. Radiology 1993;188:517-21.
77. Breitfeld PP, Meyer WH. Rhabdomyosarcoma: New windows of opportunity. Oncologist 2005;10:518-27.
78. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: Current management. Oncologist 2006;11:503-19.
79. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: Comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-36.